Zyprexa marketing documents subpoenaed in Florida

Lilly says it is complying with a request from the Florida Attorney General's Medicaid Fraud Control Unit for documents relating to sales, marketing and promotional practices for Zyprexa; other Lilly products could become subject to investigation, company's 10-Q filing states. Lilly says subpoena is unrelated to removal of Zyprexa and Symbyax from the state's Medicaid preferred drug list (1"The Pink Sheet" July 11, 2005, p. 11)...

Lilly says it is complying with a request from the Florida Attorney General's Medicaid Fraud Control Unit for documents relating to sales, marketing and promotional practices for Zyprexa ; other Lilly products could become subject to investigation, company's 10-Q filing states. Lilly says subpoena is unrelated to removal of Zyprexa and Symbyax from the state's Medicaid preferred drug list (¹ (Also see "Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List" - Pink Sheet, 11 Jul, 2005.), p. 11)....